Testosterone replacement therapy (TRT) is an evidence-based treatment option for men with symptomatic testosterone deficiency (male hypogonadism) confirmed by laboratory testing. When appropriately prescribed and monitored, TRT can improve select symptoms related to androgen deficiency while maintaining an acceptable safety profile. However, therapy requires careful patient selection, shared decision-making, and ongoing surveillance.

This guide provides a clinical overview of diagnosis, benefits, risks, formulations, monitoring, and special populations, based on current guidelines and recent high-quality clinical trials.

Understanding Testosterone Deficiency (Male Hypogonadism)

Testosterone deficiency occurs when the testes do not produce adequate levels of testosterone to meet physiologic needs. Diagnosis requires both symptoms and biochemical confirmation—testosterone levels alone are insufficient.

Common Clinical Symptoms

Symptoms of hypogonadism are often nonspecific and may overlap with aging or chronic disease. Common features include:

• Decreased libido and sexual dysfunction

• Erectile dysfunction

• Reduced muscle mass and strength

• Increased fat mass

• Fatigue and low energy

• Mood changes or irritability

• Decreased bone density

• Loss of body or facial hair

Because these symptoms may have multifactorial causes, objective laboratory confirmation is essential before initiating therapy.

Diagnostic Criteria for Testosterone Deficiency

Biochemical Confirmation

Diagnosis requires:

• Two or more fasting, early-morning total testosterone measurements

• Levels generally below 300 ng/dL (10.4 nmol/L)

• Testing should be performed on separate days

If total testosterone levels are borderline, free testosterone should be assessed to account for variations in sex hormone–binding globulin (SHBG).

Additional Hormonal Evaluation

• LH and FSH help distinguish:

  • Primary hypogonadism (testicular failure)

  • Secondary hypogonadism (hypothalamic-pituitary dysfunction)

Men with very low testosterone levels (<200 ng/dL) are more likely to experience meaningful clinical benefit from TRT. Those with mildly reduced levels—particularly in the setting of obesity or metabolic disease—may derive less improvement.

Benefits of Testosterone Replacement Therapy

Sexual Function

TRT produces modest but statistically significant improvements in:

• Libido

• Erectile function

• Sexual activity

• Sexual satisfaction

Improvements in libido are consistent, whereas erectile dysfunction may respond less reliably when vascular disease is the primary driver.

Body Composition

TRT increases lean body mass and reduces fat mass, though the clinical impact varies between individuals.

Bone Health

Treatment increases bone mineral density at the spine and hip and may improve bone strength, particularly in men with osteoporosis.

Anemia

In hypogonadal men with anemia, TRT may normalize hemoglobin levels and improve energy.

Metabolic Effects

TRT may improve insulin sensitivity and metabolic parameters, particularly in men with severe insulin resistance or prediabetes.

Mood and Cognitive Effects

Current evidence shows inconsistent or minimal improvement in depression, cognition, or vitality at a population level, though individual responses vary.

Risks and Safety Considerations

Cardiovascular Risk

Large randomized trials demonstrate that TRT does not increase the risk of major adverse cardiovascular events, myocardial infarction, or stroke—even in men with elevated baseline cardiovascular risk. However, an increased incidence of atrial fibrillation has been observed.

Thromboembolic Risk

TRT has been associated with a small increased risk of pulmonary embolism. Absolute risk remains low, but men with prior thromboembolic disease require careful consideration.

Prostate Health

Clinical trials have not demonstrated increased prostate cancer risk or worsening of lower urinary tract symptoms. However, men at high prostate risk were excluded from trials, underscoring the need for appropriate screening.

Hematologic Effects

TRT commonly causes erythrocytosis (elevated hematocrit), which increases thrombotic risk and requires routine monitoring. Dose adjustment or therapeutic phlebotomy may be necessary.

Fertility Suppression

TRT suppresses spermatogenesis and should not be used in men actively pursuing fertility. An alternative that preserves fertility is Enclomiphene Therapy Jacksonville.

Absolute Contraindications to TRT

TRT should not be initiated in men with:

• Breast or prostate cancer

• Palpable prostate nodule or induration

• PSA >4 ng/mL (or >3 ng/mL in high-risk men without urologic evaluation)

• Elevated hematocrit

• Recent myocardial infarction or stroke (within 4–6 months)

• Severe or decompensated heart failure

• Severe untreated obstructive sleep apnea

• Known thrombophilia

• Active fertility treatment

Testosterone Formulations and Dosing

Treatment Goals

The goal of TRT is to maintain testosterone levels in the mid-normal physiologic range, typically:

• 450–600 ng/dL (or 300–900 ng/dL depending on assay)

Common Formulations

Intramuscular Injections

• Testosterone cypionate or enanthate

• 75–100 mg weekly or 150–200 mg every 2 weeks

• Advantages: Cost-effective, well-studied

• Disadvantages: Hormonal fluctuations, injection site reactions

• Often preferred as initial therapy due to cost and efficacy

Transdermal Preparations

• Daily gels or patches

• Advantages: Stable levels, easy discontinuation

• Disadvantages: Skin irritation, higher cost, risk of transfer to others

• Preferred for initiation in older men

Other Options

• Subcutaneous pellets

• Buccal tablets

• Nasal gels

Selection should reflect shared decision making considering patient preference, cost, pharmacokinetics, safety profile, and adherence considerations.

Monitoring and Follow-Up

First Year of Therapy

• 3 months: Testosterone level, hematocrit, symptom assessment, PSA (men ≥40)

• 6 months: Repeat evaluations

• 12 months: Comprehensive reassessment

Ongoing Monitoring

• Annual or more frequent as indicated:

  • Testosterone levels

  • Hematocrit (intervene if >54%)

  • PSA monitoring

  • Bone density (if osteoporosis present)

  • Assessment for adverse effects

TRT should be discontinued if no clinical improvement is observed within 12 months.

Special Populations

Older Men

TRT should be offered cautiously and only to symptomatic men with confirmed deficiency after discussing uncertainties surrounding long-term safety. Short-acting formulations are preferred initially.

Men With Cardiovascular Disease

TRT should be avoided within 4–6 months of myocardial infarction or stroke. In stable disease, individualized risk-benefit assessment is required.

Men With Obesity or Metabolic Syndrome

Lifestyle modification should be prioritized. TRT may be considered if symptoms and biochemical hypogonadism persist despite weight loss and metabolic optimization.

Duration of Therapy

There is no predefined limit to TRT duration. Treatment should continue as long as benefits outweigh risks and monitoring remains appropriate. Withdrawal may be considered if underlying causes of hypogonadism resolve.

Clinical Decision-Making Framework

Initiation of TRT should involve shared decision-making that weighs:

1. Symptom burden and quality-of-life impact

2. Degree of testosterone deficiency

3. Individual risk profile

4. Patient goals and preferences

5. Cost and long-term treatment burden

Meaningful benefit is expected only in men with unequivocal hypogonadism confirmed by symptoms and laboratory evidence.

Conclusion

In conclusion, testosterone replacement therapy is an effective, evidence-based treatment for appropriately selected men with confirmed symptomatic hypogonadism. When guided by a comprehensive diagnostic process, TRT can improve sexual function, body composition, bone density, and select metabolic parameters, while maintaining an acceptable safety profile through structured monitoring. A thorough evaluation—including symptom assessment, repeat laboratory confirmation, and risk stratification—is essential before initiating therapy.

At Intercoastal Health, testosterone therapy is delivered within a broader, individualized care model that emphasizes precision diagnostics, ongoing monitoring, and long-term health optimization. Younger patients who wish to have children may benefit from Enclomiphene Therapy Jacksonville that preserves fertility; learn more about the benefits here.By integrating traditional hormone replacement strategies with a comprehensive functional medicine evaluation, clinical care extends beyond hormone normalization to address contributing metabolic, cardiovascular, and lifestyle factors that influence overall outcomes.

For patients who may benefit from adjunctive or supportive therapies, targeted peptide therapy may be considered to support tissue repair, recovery, and physiologic resilience as part of an individualized treatment plan. This integrated, data-driven approach allows for safer, more effective testosterone optimization tailored to each patient’s goals and risk profile.